Background: Renal ischemia-reperfusion (I/R) injury is a major cause of acute renal failure (ARF). The transcription factor nuclear factor-κB (NF-κB) has been implicated as a key mediator of reperfusion injury. Activation of NF-κB is dependent upon the phosphorylation of its inhibitor, IκB, by the specific inhibitory κB kinase (IKK) subunit, IKKβ. We hypothesized that ischemic preconditioning (IPC) reduces acute renal damage following I/R injury by inhibiting activation of IKKβ. As neutrophil gelatinase-associated lipocalin (NGAL), an early predictive biomarker of acute kidney injury, is regulated by NF-κB, we approached the relationship between NGAL and IKKβ. Method: Thirty male Sprague-Dawley rats were randomly divided into 3 groups after right kidney nephrectomy. Group A rats were sham-operated controls. Group B rats were 45-min ischemic in the left renal artery while Group C rats were pre-treated with 3 cycles of 2-min ischemia and 5-min reperfusion. All the rats were sacrificed at 24 h after reperfusion. We harvested kidneys and serum to do further analysis, including histological and functional parameters, expressions of NGAL and IKKβ in renal tissues. Results: Compared with rats subjected to I/R injury, pre-treated rats had a significant decrease in serum creatinine level (Scr) and tubulointerstitial injury scores (Scr, 86.79 ± 12.98 vs. 205.89 ± 19.16 μmol/l, p < 0.01; tubulointerstitial injury scores, 1.3 ± 0.48 vs. 3.8 ± 0.79, p < 0.01). In addition, expressions of IKKβ (0.95 ± 0.21 vs. 1.74 ± 0.17, p < 0.05) and NGAL (1.71 ± 0.032 vs. 2.66 ± 0.078, p < 0.05) at renal tubule in pre-treated rats were attenuated significantly compared with rats subjected to ischemia-reperfusion injury. Moreover, our study showed that IKKβ and NGAL were in positive correlation (R = 0.965 > R0.01(30) = 0.448, p < 0.01). Conclusions: The evidence suggests that IKKβ may play a role in renal I/R injury and give rise to the generation of NGAL. It appears that IPC may attenuate renal injury and the expression of NGAL following acute I/R injury. IKKβ may offer a clinically accessible target for preventing renal injury following I/R.

Schrier RW, Wang W, Poole B, Mitra A: Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004;114:5–14.
Lameire N, Van BW, Vanholder R: Acute renal failure. Lancet 2005;365:14.
Devarajan P: Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006;17:1503–1520.
Goldstein SL: Pediatric acute kidney injury: it’s time for real progress. Pediatr Nephrol 2006;21:891–895.
Rosner MH, Okusa MD: Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006;1:19–32.
Sung FL, Zhu TY, Au-Yeung KK, Siow YL, et al: Enhanced MCP-1 expression during ischemia/reperfusion injury is mediated by oxidative stress and NF-kappaB. Kidney Int 2002;62:1160–1170.
Burne-Taney MJ, Liu M, Baldwin WM, Racusen L, et al: Decreased capacity of immune cells to cause tissue injury mediates kidney ischemic preconditioning. J Immunol 2006;176:7015–7020.
Jo SK, Ko GJ, Boo CS, Cho WY, et al: Heat preconditioning attenuates renal injury in ischemic ARF in rats: role of heat-shock protein 70 on NF-kappaB-mediated inflammation and on tubular cell injury. J Am Soc Nephrol 2006;17:3082–3092.
Joo JD, Kim M, D’Agati VD, Lee HT: Ischemic preconditioning provides both acute and delayed protection against renal ischemia and reperfusion injury in mice. J Am Soc Nephrol 2006;17:3115–3123.
Moss NC, Stansfield WE, Willis MS, Tang RH, et al: IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007;293:H2248–H2253.
Bennett M, Dent CL, Ma Q, Dastrala S, et al: Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008;3:665–673.
Mishra J, Mori K, Ma Q, Kelly C, et al: Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004;15:3073–3082.
DiDonato JA: Assaying for IkappaB kinase activity. Methods Enzymol 2000;322:393–400.
Trushin S, Pennington K, Carmona E: Protein kinase C alpha (PKC alpha) acts upstream of PKC theta to activate IκB kinase and NF-κB in T lymphocytes. Mol Cell Biol 2003;23:7068–7081.
Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124–1136.
Ferencz A, Racz B, Gasz B, Benko L, et al: Intestinal ischemic preconditioning in rats and NF-kappaB activation. Microsurgery 2006;26:54–57.
Lee HT, Emala CW: Protein kinase C and G(i/o) proteins are involved in adenosine- and ischemic preconditioning-mediated renal protection. J Am Soc Nephrol 2001;12:233–240.
Torras J, Herrero-Fresneda I, Lloberas N, Riera M, et al: Promising effects of ischemic preconditioning in renal transplantation. Kidney Int 2002;61:2218–2227.
Sola A, Palacios L, Lopez-Marti J, Ivorra A, et al: Multiparametric monitoring of ischemia-reperfusion in rat kidney: effect of ischemic preconditioning. Transplantation 2003;75:744–749.
Jefayri MK, Grace PA, Mathie RT: Attenuation of reperfusion injury by renal ischaemic preconditioning: the role of nitric oxide. BJU Int 2000;85:1007–1013.
Chander V, Chopra K: Role of nitric oxide in resveratrol-induced renal protective effects of ischemic preconditioning. J Vasc Surg 2005;42:1198–1205.
Yamashita J, Ogata M, Itoh M, Yamasowa H, et al: Role of nitric oxide in the renal protective effects of ischemic preconditioning. J Cardiovasc Pharmacol 2003;42:419–427.
Timsit M, Gadet R, Ben Abdennebi H, Codas R, et al: Renal ischemic preconditioning improves recovery of kidney function and decreases alpha-smooth muscle actin expression in a rat model. J Urol 2008;180:388–391.
Li P, Ding XQ, Cao CC: Experimental study of renal ischemic preconditioning and the role of ICAM-1. China J Nephrol 2004;29.
Jiang S, Liu C, Zhang X, Xu X, et al: Renal protection by delayed ischaemic preconditioning is associated with inhibition of the inflammatory response and NF-kappaB activation. Cell Biochem Funct 2007;25:335–343.
Baldwin AS Jr: Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 2001;107:3–6.
Hall G, Singh IS, Hester L, Hasday JD, et al: Inhibitor-kappaB kinase-beta regulates LPS-induced TNF-alpha production in cardiac myocytes through modulation of NF-kappaB p65 subunit phosphorylation. Am J Physiol Heart Circ Physiol 2005;289:H2103–H2111.
Li C, Kao RL, Ha T, Kelley J, et al: Early activation of IKKbeta during in vivo myocardial ischemia. Am J Physiol Heart Circ Physiol 2001;280:H1264–H1271.
Valen G, Yan ZQ, Hansson GK: Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001;38:307–314.
Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, et al: Differential gene expression following early renal ischemia/reperfusion. Kidney Int 2003;63:1714–1724.
Mishra J, Ma Q, Prada A, Mitsnefes M, et al: Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534–2543.
Mishra J, Mori K, Ma Q, Kelly C, et al: Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004;24:307–315.
Mori K, Lee HT, Rapoport D, Drexler IR, et al: Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005;115:610–621.
Schmidt-Ott KM, Mori K, Kalandadze A, Li JY, et al: Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia. Curr Opin Nephrol Hypertens 2006;15:442–449.
Tuttle KR, Worrall NK, Dahlstrom LR, Nandagopal R, et al: Predictors of ARF after cardiac surgical procedures. Am J Kidney Dis 2003;41:76–83.
Bu DX, Hemdahl AL, Gabrielsen A, Fuxe J, et al: Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am J Pathol 2006;169:2245–2253.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.